USE OF NTCP INHIBITORS IN PREVENTING AND TREATING HEPATOCARCINOGENESIS

摘要

The invention provides use of NTCP inhibitors in preventing and/or treating hepatocarcinogenesis. The hepatocarcinogenesis may induced by HBV and/or HDV infection (s), fatty liver disease or chemical (s). The hepatocarcinogenesis may happen in males. In some cases, the NTCP inhibitor down-regulates or inhibits the expression of NTCP. In other cases, the NTCP inhibitor regulates the function of NTCP, preferably, inhibits the function of NTCP or makes the NTCP dysfunction. Preferably, the NTCP inhibitor is cyclosporine A or comprising at least one compound with the structure of formula I or its pharmaceutically acceptable salts.